1993 (v1)
Publication
No description
Uploaded on: December 5, 2022
G
M
GOBBI , Marco
Last name: GOBBI
First name: Marco
Email: marco.gobbi@emeriti.unige.it
Institution: UNIGE
Links
-
-
1983 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2012 (v1)Publication
No description
Uploaded on: March 31, 2023 -
1998 (v1)Publication
No description
Uploaded on: December 5, 2022 -
2004 (v1)Publication
The introduction of tyrosine kinase inhibition Imatinib in the treatment of CML has revolutionized the history of the disease making obsolete all the previous therapies; however, in selected cases, old drugs retain their value.
Uploaded on: April 14, 2023 -
2009 (v1)Publication
No description
Uploaded on: April 14, 2023 -
1998 (v1)Publication
No description
Uploaded on: December 5, 2022 -
1989 (v1)Publication
No description
Uploaded on: December 5, 2022 -
2013 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2011 (v1)Publication
No description
Uploaded on: April 14, 2023 -
1982 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2016 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2012 (v1)Publication
No description
Uploaded on: April 14, 2023 -
1985 (v1)Publication
No description
Uploaded on: April 14, 2023 -
1999 (v1)Publication
No description
Uploaded on: March 31, 2023 -
1997 (v1)Publication
No description
Uploaded on: December 5, 2022 -
2009 (v1)Publication
Engagement of NKG2D by their ligands (NKG2D-L), as the human major histocompatibility complex class I-related molecules MIC-A and the UL16-binding proteins, on cytolytic lymphocytes leads to the enhancement of antitumour effector functions. These ligands are missing or expressed at very low levels on leukaemic cells; furthermore, they can be...
Uploaded on: March 31, 2023 -
1993 (v1)Publication
No description
Uploaded on: March 31, 2023 -
1997 (v1)Publication
No description
Uploaded on: December 5, 2022 -
2008 (v1)Publication
No description
Uploaded on: March 25, 2023 -
1991 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2017 (v1)Publication
Acute Myeloid Leukemia (AML) is the commonest form of leukemia in the adults, with an incidence of 3-4 cases per 100,000 people/year. After the first description of the effective cytarabine + antracycline (3+7) induction regimen, in the last 3 decades, no effective targeted drug has been included in the standard treatment of AML. Many efforts...
Uploaded on: April 14, 2023 -
1996 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2007 (v1)Publication
No description
Uploaded on: April 14, 2023